KPV

weak data

Also seen as: Lys-Pro-Val

The Dose Guy’s verdict

Sep 1, 2026
3 sources

KPV has the cleanest anti-inflammatory mechanism in this column and the strongest rodent data for gut inflammation. No human trial. Zero. The community runs it for IBD-like symptoms and gut repair, and enough people report relief that I will not write it off. But the entire evidence base is dishes and mice, and you are dosing yourself on the community’s word, not a study’s.

Would I take it?Maybe, for gut, if you accept the risk.

What it is

A tripeptide clipped from the C-terminal end of alpha-melanocyte-stimulating hormone. KPV carries the parent hormone’s anti-inflammatory activity without its melanocortin receptor binding, which is why it can be dosed as a standalone peptide without the pigmentation effects.

The mechanism is direct: KPV enters cells through the PepT1 transporter, parks itself in the nucleus, and blocks NF-kB, the master switch for inflammatory signaling. PepT1 is expressed heavily in intestinal epithelium, which is why the community adopted KPV for gut inflammation rather than systemic healing. BPC-157 is the more popular gut peptide, but BPC-157’s evidence for gut is also preclinical. KPV targets inflammation more specifically where BPC-157 targets repair more broadly.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

Strong preclinical story, entirely in cells and rodents. No human interventional data of any kind:

KPV was transported into immune and intestinal epithelial cells by the PepT1 transporter. At nanomolar concentrations it inhibited NF-kB and MAP kinase inflammatory signaling. Oral KPV reduced DSS-induced and TNBS-induced colitis in mice.Gastroenterology 2008 · cells + mice

In DSS mouse colitis, KPV produced earlier recovery, stronger body-weight regain, and reduced colonic myeloperoxidase activity. In mice with nonfunctional MC1 receptors, KPV rescued every treated animal from death.Inflamm Bowel Dis 2008 · mouse colitis

Colon-targeted nanoparticles delivered KPV at a concentration 12,000-fold lower than free KPV while retaining similar efficacy in a DSS mouse colitis model.Gastroenterology 2010 · nanoparticle delivery

No human interventional trial testing KPV exists. No clinical efficacy result. No human safety dataset.as of Aug 2026

Realistic protocols

The community runs KPV orally for gut inflammation and subcutaneously for skin or systemic effects. Oral makes the most mechanistic sense for gut issues, since PepT1 sits on the intestinal lining and that is where you want KPV to land. Sub-q bypasses the transporter that the entire preclinical story is built on, so if your goal is gut inflammation, oral is the route that matches the science.

Typical oral doses are 200 to 500 mcg once or twice a day, taken on an empty stomach. Sub-q doses are similar. For sub-q use, reconstitute with bacteriostatic water and refrigerate. Some people run KPV alongside BPC-157 for gut issues, combining KPV’s anti-inflammatory action with BPC-157’s repair signal. Cycles run four to eight weeks, reassess after four. These numbers come from community practice, not from a study.

If you are running KPV for gut symptoms, the two things most likely undoing your progress are alcohol and NSAIDs. Both inflame the gut lining you are trying to calm down. Cut them while you run it, or you are paying for a peptide to fight a fire you keep lighting.

Oral (gut)200–500 mcg/dayEmpty stomach. The route that matches the PepT1 mechanism.

Sub-q200–500 mcg/dayFor skin or systemic inflammation. Less mechanistic support than oral for gut.

The pair+ BPC-157 oralKPV for inflammation, BPC-157 for repair. Community gut stack.

Duration4–8 weeksReassess at four. No data to guide longer runs.

Side effects

No human safety dataset exists. What people report:

anecdotalMild nausea on oral dosing, usually in the first few days and usually at higher doses.

anecdotalSlight skin tanning or freckling reported by some. The mechanism is unclear given that KPV’s anti-inflammatory effect appears to be melanocortin-receptor-independent in the studies tested.

unknownNo human adverse-event data of any kind. The anti-inflammatory effect is well characterized in rodents, but what KPV does to a person’s immune regulation over weeks of dosing is unknown.